Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Depreciation and Depletion (2016 - 2025)

Altimmune (ALT) has disclosed Depreciation and Depletion for 14 consecutive years, with $27000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion fell 27.03% to $27000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $119000.0, a 62.7% decrease, with the full-year FY2024 number at $238000.0, down 50.1% from a year prior.
  • Depreciation and Depletion was $27000.0 for Q3 2025 at Altimmune, down from $30000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $131550.0 in Q4 2021 to a low of $27000.0 in Q3 2025.
  • A 5-year average of $81312.5 and a median of $100000.0 in 2021 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 68.05% in 2021, then tumbled 72.9% in 2025.
  • Altimmune's Depreciation and Depletion stood at $131550.0 in 2021, then decreased by 23.98% to $100000.0 in 2022, then rose by 14.0% to $114000.0 in 2023, then crashed by 71.05% to $33000.0 in 2024, then dropped by 18.18% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Depreciation and Depletion are $27000.0 (Q3 2025), $30000.0 (Q2 2025), and $29000.0 (Q1 2025).